Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENTS (Details Narrative)

v3.24.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
 12 Months Ended
Mar. 19, 2024
Feb. 08, 2024
Feb. 06, 2024
Mar. 09, 2022
Mar. 04, 2022
Dec. 31, 2023
Dec. 31, 2022
Subsequent Event [Line Items]              
Reverse stock split       all shares adjusted to reflect a 40:1 reverse stock split effected on March 9, 2022 Company completed a 40:1 reverse stock split of its common shares.   40:1 Reverse Split
Preferred stock, shares outstanding           1,509 1,509
Total common shares issued           1,330,363 626,917
Common stock, shares outstanding           3,609,382 2,279,019
Series B Preferred Stock [Member]              
Subsequent Event [Line Items]              
Preferred stock, shares outstanding           1,509 1,509
Series A Preferred Stock [Member]              
Subsequent Event [Line Items]              
Number of conversion shares           80,000  
Subsequent Event [Member]              
Subsequent Event [Line Items]              
Reverse stock split     1:1000 and 1:2000        
Common stock, shares outstanding 4,445,469            
Stock options exercised 150,611            
Subsequent Event [Member] | Second Amendment [Member] | IGL Pharma, Inc. [Member]              
Subsequent Event [Line Items]              
Additional payment     $ 100,000        
Subsequent Event [Member] | Series B Preferred Stock [Member]              
Subsequent Event [Line Items]              
Preferred stock, shares outstanding     1,509        
Total common shares issued     658,967        
Subsequent Event [Member] | Series A Preferred Stock [Member]              
Subsequent Event [Line Items]              
Number of conversion shares   169,133